Therapeutic Asset Ratings

6,308 results matching 1 filter

91,564 assets · 7,904 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
hs-10375 Non-Small Cell Lung Carcinoma	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P1/2	CCC (48)
hs-10376 Non-Small Cell Lung Carcinoma	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P1/2	CCC (48)
htl0039732 capsules Pheochromocytoma	Cancer Research UK	P1/2	CCC (48)
htl0039732 capsules Urinary Bladder Neoplasm	Cancer Research UK	P1/2	CCC (48)
hul001 Plasma Cell Myeloma	HuniLife Biotechnology, Inc.	P1/2	CCC (48)
Human Allogeneic Induced Pluripotent Stem Cell -Derived Dopaminergic Neural Progenitor Cell Parkinson Disease	XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.	P1/2	CCC (48)
HUMAN AMNIOTIC FLUID Multiple Sclerosis	Wake Forest University Health Sciences	P1/2	CCC (48)
HUMAN FAECAL MATTER Alcoholic Liver Disease	Virginia Commonwealth University	P1/2	CCC (48)
HUMAN IMMUNOGLOBULINS Non-Small Cell Lung Carcinoma	VA Office of Research and Development	P1/2	CCC (48)
Humanized Monoclonal Anti-Fgfr1 Antibody Om-Rca-01 Non-Small Cell Lung Carcinoma	Kidney Cancer Research Bureau	P1/2	CCC (48)
Humanized Monoclonal Anti-Fgfr1 Antibody Om-Rca-01 Renal Cell Carcinoma	Kidney Cancer Research Bureau	P1/2	CCC (48)
HUMAN RELAXIN 1 Cardiac Rhythm Disease	Deeptankar DeMazumder	P1/2	CCC (48)
HUMAN RELAXIN 1 Atrial Fibrillation	Deeptankar DeMazumder	P1/2	CCC (48)
HUMAN RELAXIN 1 Cardiovascular Disorder	Deeptankar DeMazumder	P1/2	CCC (48)
human T-lymphocyte activation antigen CD80 (activation B7-1 antigen, CTLA-4 counter-receptor B7.1, CD80) extracellular domain containing fragment (1-208 in the current sequence) fused via peptide linker <sup>209</sup>GSGGGGSGGGGSGGGGS<sup>225</sup> to an Fc fragment of human immunoglobulin G4 (226-454) [Homo sapiens IGHG4*01, hinge ins<sup>226</sup>>A, S<sup>236</sup>>P (226-238), CH2 F<sup>242</sup>>A, L<sup>243</sup>>A, T<sup>258</sup>>Q (239-348), CH3 M<sup>436</sup>>L (349-453), CHS K<sup>455</sup>>del (454)] fused via peptide/ linker <sup>455</sup>GGGGS<sup>459</sup> to human interleukin-2 (IL-2, T-cell growth factor (TCGF)) (1-133, 460-592 in the current sequence), variant (R<sup>38</sup>>A<sup>497</sup>, F<sup>42</sup>>A<sup>501</sup>), dimer (234-234', 237-237')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa Nonpapillary Renal Cell Carcinoma	GI Innovation, Inc.	P1/2	CCC (48)
human T-lymphocyte activation antigen CD80 (activation B7-1 antigen, CTLA-4 counter-receptor B7.1, CD80) extracellular domain containing fragment (1-208 in the current sequence) fused via peptide linker <sup>209</sup>GSGGGGSGGGGSGGGGS<sup>225</sup> to an Fc fragment of human immunoglobulin G4 (226-454) [Homo sapiens IGHG4*01, hinge ins<sup>226</sup>>A, S<sup>236</sup>>P (226-238), CH2 F<sup>242</sup>>A, L<sup>243</sup>>A, T<sup>258</sup>>Q (239-348), CH3 M<sup>436</sup>>L (349-453), CHS K<sup>455</sup>>del (454)] fused via peptide/ linker <sup>455</sup>GGGGS<sup>459</sup> to human interleukin-2 (IL-2, T-cell growth factor (TCGF)) (1-133, 460-592 in the current sequence), variant (R<sup>38</sup>>A<sup>497</sup>, F<sup>42</sup>>A<sup>501</sup>), dimer (234-234', 237-237')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa Non-Small Cell Squamous Lung Carcinoma	GI Innovation, Inc.	P1/2	CCC (48)
Hydrocortisone Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	Children's Oncology Group	P1/2	CCC (48)
Hydroxyurea Diamond-Blackfan Anemia	Paul Szabolcs	P1/2	CCC (48)
Hydroxyurea Chronic Obstructive Pulmonary Disease	Paul Szabolcs	P1/2	CCC (48)
iap0971 Cancer	SUNHO（China）BioPharmaceutical CO., Ltd.	P1/2	CCC (48)
ibb0979 Cancer	SUNHO（China）BioPharmaceutical CO., Ltd.	P1/2	CCC (48)
Iberdomide B-Cell Non-Hodgkin Lymphoma	Celgene	P1/2	CCC (48)
Ibrutinib Central Nervous System Neoplasm	Institut Curie	P1/2	CCC (48)
Ibrutinib Refractory Hematologic Cancer	Curis, Inc.	P1/2	CCC (48)
Ibrutinib Hematopoietic And Lymphoid System Neoplasm	Curis, Inc.	P1/2	CCC (48)

Showing 1301 to 1325 of 6,308 assets

PreviousPage 53 of 253Next